Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

References

• Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128:683–692.
   PubMed Web of Science ®Google Scholar
• Issa JP. Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am. 2010;24:317–330.
   PubMed Web of Science ®Google Scholar
• Conway O'Brien E, Prideaux S, Chevassut T. The epigenetic landscape of acute myeloid leukemia. Adv Hematol. 2014;2014:103175.
   PubMedGoogle Scholar
• Peirs S, Van der Meulen J, Van de Walle I, et al. Epigenetics in T-cell acute lymphoblastic leukemia. Immunol Rev. 2015;263:50–67.
   PubMed Web of Science ®Google Scholar
• New M, Olzscha H, La Thangue NB. HDAC inhibitor-based therapies: can we interpret the code? Mol Oncol. 2012;6:637–656.
   PubMed Web of Science ®Google Scholar
• Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–784.
   PubMed Web of Science ®Google Scholar
• Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90:85–94.
   PubMed Web of Science ®Google Scholar
• West AC, Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Investig. 2014;124:30–39.
   PubMed Web of Science ®Google Scholar
• Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013;124:651–662.
   PubMed Web of Science ®Google Scholar
• Zolinza (vorinostat) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2015.
   Google Scholar
• Istodax (romidepsin) [prescribing information]. Summit, NJ: Celgene Corporation; 2014.
   Google Scholar
• Beleodaq (belinostat) [prescribing information]. Irvine, CA: Spectrum, Pharmaceuticals, Inc.; 2014.
   Google Scholar
• Farydak (panobinostat). East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015.
   Google Scholar
• Farydak (panobinostat) [summary of product characteristics]. Nuremberg, Germany: Novartis Pharma GmbH; 2015.
   Google Scholar
• Chambers AE, Banerjee S, Chaplin T, et al. Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer. 2003;39:1165–1175.
   PubMed Web of Science ®Google Scholar
• Einsiedel HG, Kawan L, Eckert C, et al. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia. Leukemia. 2006;20:1435–1436.
   PubMed Web of Science ®Google Scholar
• Scuto A, Kirschbaum M, Kowolik C, et al. The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph- acute lymphoblastic leukemia cells. Blood. 2008;111:5093–5100.
   PubMed Web of Science ®Google Scholar
• Gore SD, Weng LJ, Figg WD, et al. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res. 2002;8:963–970.
   PubMed Web of Science ®Google Scholar
• Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer. 2006;106:112–119.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Assouline S, Cortes J, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. Blood. 2008;112:981–989.
   PubMed Web of Science ®Google Scholar
• Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–1066.
   PubMed Web of Science ®Google Scholar
• Schaefer EW, Loaiza-Bonilla A, Juckett M, et al. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica. 2009;94:1375–1382.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Marcucci G, Parthun MR, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood. 2005;105:959–967.
   PubMed Web of Science ®Google Scholar
• Klimek VM, Fircanis S, Maslak P, et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin Cancer Res. 2008;14:826–832.
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109:2781–2790.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Spencer A, Bhalla KN, et al. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. Leukemia. 2013;27:1628–1636.
   PubMed Web of Science ®Google Scholar
• Giles F, Fischer T, Cortes J, et al. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res. 2006;12:4628–4635.
   PubMed Web of Science ®Google Scholar
• Odenike OM, Alkan S, Sher D, et al. Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia. Clin Cancer Res. 2008;14:7095–7101.
   PubMed Web of Science ®Google Scholar
• Rivera-Del Valle N, Gao S, Miller CP, et al. PCI-24781, a novel hydroxamic acid HDAC inhibitor, exerts cytotoxicity and histone alterations via caspase-8 and FADD in leukemia cells. Int J Cell Biol. 2010;2010:207420.
   PubMedGoogle Scholar
• Buggy JJ, Cao ZA, Bass KE, et al. CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo. Mol Cancer Ther. 2006;5:1309–1317.
   PubMed Web of Science ®Google Scholar
• Evens AM, Balasubramanian S, Vose JM, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res. 2016;22:1059–1066.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Terriou L, Coiffier B, et al. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Investig New Drugs. 2015;33:423–431.
   PubMed Web of Science ®Google Scholar
• Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425.
   PubMed Web of Science ®Google Scholar
• Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood. 2011;117:3658–3668.
   PubMed Web of Science ®Google Scholar
• Ali A, Bluteau O, Messaoudi K, et al. Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms. Cell Death Dis. 2013;4:e738.
   PubMed Web of Science ®Google Scholar
• Kristeleit R, Fong P, Aherne GW, et al. Histone deacetylase inhibitors: emerging anticancer therapeutic agents? Clin Lung Cancer. 2005;7:S19–S30.
   PubMed Web of Science ®Google Scholar
• Molife R, Fong P, Scurr M, et al. HDAC inhibitors and cardiac safety. Clin Cancer Res. 2007;13:1068. Author reply 1068–1069.
   PubMed Web of Science ®Google Scholar
• Ribrag VK, Kim WS, Bouabdallah R, et al. Safety and efficacy of abexinostat, a pan-histone deacetylase (HDAC) inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of an ongoing phase 2 study [abstract]. Blood. 2015;126:Abstract 256.
   PubMed Web of Science ®Google Scholar
• Thurn KT, Thomas S, Moore A, et al. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011;7:263–283.
   PubMed Web of Science ®Google Scholar
• Gore SD, Baylin S, Sugar E, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369.
   PubMed Web of Science ®Google Scholar
• Stahl M, Gore SD, Vey N, et al. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2016;25:307–317.
   PubMed Web of Science ®Google Scholar
• Prebet T, Sun Z, Figueroa ME, et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J Clin Oncol. 2014;32:1242–1248.
   PubMed Web of Science ®Google Scholar
• Issa JP, Garcia-Manero G, Huang X, et al. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer. 2015;121:556–561.
   PubMed Web of Science ®Google Scholar
• Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107.
   PubMed Web of Science ®Google Scholar
• Mummery A, Narendran A, Lee KY. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets. 2011;11:882–893.
   PubMed Web of Science ®Google Scholar
• Sekeres M, Othus M, List AF, et al. Additional analyses of a randomized phase II study of azacitidine combined with lenalidomide or with vorinostat vs. azacitidine monotherapy in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117 [abstract]. Blood. 2015;126:Abstract 908.
   PubMed Web of Science ®Google Scholar